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Abstract 
Dilated cardiomyopathy is a serious and almost inevitable complication of Duchenne Muscular 
Dystrophy, a devastating and fatal disease of skeletal muscle resulting from the lack of 
functional dystrophin, a protein linking the cytoskeleton to the extracellular matrix. Ultimately, it 
leads to congestive heart failure and arrhythmias resulting from both cardiac muscle fibrosis and 
impaired function of the remaining cardiomyocytes. Here we summarize findings obtained in 
several laboratories, focussing on cellular mechanisms that result in degradation of cardiac 
functions in dystrophy.
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Non-standard Abbreviations and Acronyms 
 
ACE  Angiotensin converting enzyme 
CaMKII Ca2+/calmodulin-dependent protein kinase II 
CaV3  Caveolin 3 
CICR   Ca2+-induced Ca2+ release 
DMD  Duchenne muscular dystrophy 
ECC  Excitation-Contraction Coupling 
ISO  Isoproterenol 
NCX  Na+-Ca2+ exchanger 
NOX  Nicotinamide adenine dinucleotide phosphate-oxidase 
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1. Introduction 
Duchenne Muscular Dystrophy (DMD) is an inherited lethal muscular disease that affects 
primarily adolescent males. DMD was named after the French physiologist Guillaume-Benjamin 
Duchenne who presented several cases of infants with dystrophy in the mid 19th century [1]. 
DMD is usually diagnosed in early childhood. For a long time it was considered to be 
predominantly a skeletal muscle illness clinically associated with progressive debilitating muscle 
weakness, skeletal deformities and breathing disorders. Cardiac complications of this disease 
became prominent only recently as the life of DMD patients could be prolonged with improved 
therapies, such as assisted ventilation and corticosteroid treatment. About 95% of the patients 
with DMD develop cardiomyopathy by 20 years of age, and for approximately 20% of these 
patients it is limiting for survival. Abnormalities in the electrocardiogram and sinus tachycardia 
are found in a majority of DMD patients at early age. Later, echocardiography reveals motion 
abnormalities of the left ventricular walls in areas of fibrosis. Progressive spreading of fibrosis 
throughout the ventricular wall mediates a gradual enlargement of the ventricle, thinning of the 
wall and consequently a loss of contractility and heart failure. In addition to the dilated cardiac 
myopathy many DMD patients also develop arrhythmias that may lead to a sudden death [2-4]. 
Further prolongation of survival and amelioration in the quality of life for DMD patients depends 
not only on improving skeletal muscle performance but also on the development of therapies 
that slow down the progression of the cardiac disease and enhance cardiac function. This 
requires a mechanistic understanding of the nature of the cardiac defects, which can be 
obtained from studies of the cellular phenotype of the disease. This review focuses on our 
current view of cellular and molecular pathomechanisms of the dystrophic cardiomyopathy. 
 
2. Genetic and molecular underpinning of DMD 
To date, 25267 variants of the dystrophin gene are known [5]. The gene is on the Xp21 
chromosome locus and with 2.2 megabases is one of the longest human genes known. Skeletal 
and cardiac muscle of DMD patients either completely lack or express a truncated form of 
dystrophin, which in muscle is a ~427 kDa protein. Alternatively spliced isoforms expressed in a 
variety of other tissues can be substantially smaller, many are ~70 kDa. Dystrophin links the 
sarcomeric cytoskeleton to a complex of transmembrane proteins (called dystrophin-associated 
protein complex), which interacts with extracellular matrix [6,7]. In muscle, the dystrophin 
network covers almost the entire cytoplasmic surface of the plasma membrane. Dystrophin is 
also present in T-tubular membranes in cardiac myocytes [8,9]. Thus, it is strategically placed to 
serve in a variety of mechanical roles, such as maintenance of membrane stability and the 
transduction of mechanical force to the extracellular matrix. Indeed, it is widely accepted that the 
predominant functional consequence of the lack of dystrophin is an increased cellular 
vulnerability to mechanical stress associated with muscle contraction. One of the early 
diagnostic tests of DMD is to determine serum creatine kinase (CK) activity. It is increased in 
DMD patients as creatine kinase leaks through the plasmalemmal membrane of mechanically 
damaged dystrophin deficient muscle cells. Optical methods also detected accumulation of 
large molecular weight indicators inside dystrophic muscle cells getting inside through the 
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unstable cellular membrane [10-12]. However, it should be noted that the direct measurement of 
tensile strength of normal and dystrophic sarcolemma did not reveal a significant difference [13] 
and the increase in intracellular Ca2+ levels, rather the absence of dystrophin was proposed to 
underly the reduced resilience of the plasmalemma [14]. The precise molecular underpinnings 
of the membrane vulnerability resulting from the lack of dystrophin are, however, poorly 
understood at present [7]. In principle, the mechanism could be direct and mechanical, or 
indirect via Ca2+ overload or oxidative stress.  
 
3. Animal models of DMD 
3.1. The mdx mouse 
The mdx mouse is a strain of mice which arose from a spontaneous mutation (mdx) in inbred 
C57BL mice. In more recently identified dystrophin mutants, such as the mdx2cv mdx4cv mdx5cv 
mice, the spectrum and tissue distribution of the affected isoforms is different, usually more wide 
spread, and there are fewer mutation reversions [15]. Like DMD patients, mdx mice have a total 
loss of functional dystrophin from the muscle tissue. In contrast to humans, they have a less 
severe phenotype and a more slowly developing cardiac disease with a near normal life span. 
Because of their mild phenotype, there were initially some difficulties to validate mdx mice as an 
appropriate model of cardiac dystrophy. However, recent studies clearly demonstrated that mdx 
mice develop dystrophic cardiomyopathy later in life. Hearts of 2 month old mdx mice seemed to 
have normal ventricular cytosolic function and normal echocardiograms [16]. Nevertheless, 
even these young mdx hearts are more susceptible to damage when subjected to mechanical 
overload [17]. By 8 months of age, hearts from mdx mice are dilated, hypertrophied, somewhat 
fibrotic and poorly contracting [16,18]. Additionally, electrocardiographic (ECG) deviations 
gradually increase in mdx mice and by the age of 6 months significant abnormalities are 
revealed in the cardiac conduction system [19,20]. Altogether, mdx mice have some but not all 
symptoms of DMD cardiomyopathy. The manifestation is not as pronounced as in DMD and 
depends on mechanical challenges. However, because of their slowly developing phenotype 
mdx mice can be a useful model for studies of the progression of DMD and can help to identify 
the cellular sequence of events leading from the genetic defect (lack of functional dystrophin) to 
the onset of cardiac disease.  
 
3.2. The utrophin deficient mdx mouse 
Utrophin is a cytoskeletal protein which was originally described as dystrophin-like in 1989  
because of its partial homology [21]. It is widely expressed in differentiating skeletal muscle with 
the same cellular distribution as dystrophin. In adult tissue utrophin disappears from the 
sarcolemma, being replaced by dystrophin and it remains primarily localized to the 
neuromuscular junction. Utrophin expression dramatically increases in muscle from DMD 
patients and in mdx mice. It is believed that utrophin can partially compensate for the loss of 
dystrophin and to some extent explain the mild phenotype of mdx muscle (especially in skeletal 
muscle). Mdx/utrn-/- double knockout mice (DKO) exhibit most of the clinical signs of DMD 
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patients, such as short stature, kyphosis, limb weakness and breathing problems by 6 weeks of 
age [22]. All DKO mice succumb to premature death by 20 weeks of age. Compared to 
senescent mdx mice,  their  cardiac  dystrophic  phenotype  is  similar,  but  it’s  onset  is  much  earlier  
[23]. By 10 weeks of age DKO mice not only exhibit multiple histological defects, such as 
myocyte degeneration, inflammation and some fibrosis, but also abnormal ECGs and contractile 
dysfunction [24]. Therefore, the mdx/utrn-/- DKO mouse is another useful model of DMD. 
However, DKO mice are more difficult to breed. The homozygous animals do not survive birth 
and the heterozygous mice have a low rate of live-born descendants. In addition, the 
dramatically reduced life span of these mice may limit exposure to extrinsic influences, which 
may otherwise contribute to the DMD cardiomyopathy in a relevant manner [22,24]. 
 
3.3. The mdx/MyoD deficient double mutant mouse 
The myogenic differentiation factor D (MyoD) plays a key role in skeletal muscle differentiation 
and regeneration. Mdx/MyoD-/- mice display not only a pronounced skeletal muscle myopathy 
but also severe cardiomyopathy [25]. Because MyoD is not expressed in heart this peculiar 
cardiomyopathy is attributed to the progression of skeletal muscle disease. This evidence also 
supports the idea that cardiac abnormalities in DMD may not only be a result of the dystrophin 
deficiency in heart tissue, but also a consequence of skeletal muscle damage, which initiates 
stress-activated signaling pathways. Histological studies revealed large areas of fibrosis, 
associated with hypertrophied and necrotic myocytes. Notably, as in DMD hearts, the epicardial 
region of the left ventricle is prominently affected. It was suggested that the mdx/MyoD-/- mouse 
has the most faithful disease representation among the available models of DMD 
cardiomyopathy [25]. However, more functional studies are required to substantiate this claim.  
 
3.4. Canine models 
Mutations of the canine DMD gene were identified in Golden Retriever, Rottweiler, German 
Short-Hair Pointer, and Cavalier King Charles Spaniels (reviewed in [26]). Golden Retriever 
Muscular Dystrophy (GRDM) is the most thoroughly studied. Extensive muscle degeneration 
and necrosis were identified in GRDM from birth onwards and severe muscle fibrosis develops 
by 6 months of age. Respiratory failure or cardiomyopathy was frequently observed even at 
younger ages. The skeletal and cardiac characteristics of GRMD resemble those of human 
DMD more than those of mouse models. The genetic background and body size of the Golden 
Retriever is also closer to humans. Therefore, GRDM has been considered to be a useful 
animal model for human DMD. However, the size of the dog makes it difficult to maintain a 
colony. Hence this animal model is mostly used in late stages of preclinical studies of 
pharmacological interventions targeted to DMD. 
 
Overall, mdx mice and some of its additional mutant strains remain the most widely used DMD 
model for studies of cellular pathomechanisms of dystrophy. The mdx mouse is commercially 
available, is easy to breed and maintain, has a long life expectancy and a low rate of sudden 
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death. Most of the results summarized in this review were obtained using mdx mice as a DMD 
model.  
 
4. Cellular manifestations of cardiac dystrophy 
Ventricular cardiomyocytes isolated from mdx mouse heart exhibit a number of distinct 
characteristics compared to cells from wild type animals: 1) their plasmalemmal membrane is 
more fragile [10,11]; 2) ionic fluxes across the membrane are increased [11,27]; 3) resting 
cytosolic Ca2+ and Na+ levels are elevated [27-29]; 4) intracellular Ca2+ responses to mechanical 
challenges are enhanced [10,28,30]; 5) excitation-contraction coupling (EC-coupling) is 
hypersensitive [31]; and 6) the intracellular and mitochondrial redox state is shifted towards a 
more oxidative state [28,29,32]. In addition, in myocytes isolated from animals with more 
advanced stages of the disease mitochondria may undergo irreversible depolarizations and loss 
of Ca2+ from the matrix, indicating severe mitochondrial dysfunctions [28]. The findings listed 
above are pieces of the puzzle identified by current research. They have to be critically 
evaluated and put together in order to understand the cellular pathomechanisms driving 
progression of cardiac dystrophy downstream of this initial injuries. 
 
5. Cellular mechanisms of cardiac dystrophy 
As mentioned above, mdx hearts are more susceptible to damage when subjected to 
mechanical overload [17]. Histological examination revealed replacement of muscle with 
connective tissue (fibrosis), a clear indication of muscle wasting. Furthermore, analysis on the 
cellular level showed the presence of necrotic and apoptotic muscle cells [33]. Pharmacological 
and genetic inhibition of cyclophilin D and thus mitochondria-linked cell death in mdx mice 
attenuates muscular dystrophy [34]. Therefore, cell death and fibrosis are end points of the 
dystrophic damage in tissue. But what initiates the sequence of events ultimately destroying the 
cells?   A   large   body   of   research   and   a   combination   of   the   “mechanical”   and   the   “Ca2+”  
hypothesis of skeletal muscular dystrophy suggests that the augmented Ca2+ influx through 
fragile cellular membrane results in elevated intracellular Ca2+ levels, at least in some of the 
Ca2+ signaling microdomains. Together, these acute but repeatedly occurring signaling events 
may lead to serious cellular damage in the long-term. Downstream activation of Ca2+ dependent 
proteases, release of caspases and activation of associated pathways may eventually lead to 
untimely cell death by apoptosis and/or necrosis (as depicted at Diagram 1). Such events may 
in turn be the starting point for the fibrotic patches, which can be observed in dystrophic cardiac 
muscle tissue [35].  
 
 
5.1. Ca2+ influx pathways 
There are several reports of increased Ca2+ conductance in dystrophic muscle. Multiple Ca2+ 
entry pathways were examined experimentally. These studies were focused on membrane tears 
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(e.g. microruptures, [10,11,28]), stretch-activated (SACs) and stretch-inactivated channels 
[11,27,36,37]), store-operated Ca2+ entry pathways (SOCE, [37]), L-type Ca2+ channels [38] and 
transient receptor potential channels (TRP channels, [37,39,40]). Since some of these pathways 
also allow Na+ to enter the cells (e.g. SACs, tears, TRP channels), the reverse mode of Na+-
Ca2+ exchange (NCX) has also been proposed as a potential source for cytosolic Ca2+ entry 
[11].  
 
5.1.1. Membrane ruptures 
The existence of membrane ruptures or tears permeable to even relatively large molecules such 
as albumin was first found in skeletal muscle [41]. Membrane tears occur more often in mdx 
muscle fibers but are quickly resealable in most cases [37]. It seems that mdx cardiac muscle is 
also predisposed to the formation of microruptures. A substantial stretch-dependent 
internalization of the FM1-43 lipophilic fluorescent indicator was detected in dystrophic 
cardiomyocytes [10,11]. Evans Blue dye leakage into myocytes of the left ventricle was 
significantly larger in mdx mice [12]. Moreover, in vivo treatment of mdx mice or preincubation of 
isolated mdx cardiac   myocytes   with   the   membrane   sealant   “Poloxamer   188”   corrected  
increases in intracellular Ca2+ levels resulting from passive and acute stretch. It also improved 
the hemodynamic performance of the left ventricle, consistent with a reduction in the formation 
of microruptures [10,11,28]. The copolymer Poloxamer 188 has previously been shown to insert 
into artificial lipid monolayers and repair damaged biological membranes when needed [42].  
 
5.1.2. Stretch-activated channels (SACs) and TRP channels 
Inhibitors of SACs such as Gd3+, streptomycin and GsMTx-4 significantly inhibited stretch-
induced intracellular Ca2+ increases in cardiomyocytes [11,27]. The subunit composition of 
SACs is not yet known, but several TRP channels have been suggested to participate. This 
includes TRPC1, TRPC6 and TRPV2. Depending on their environment, they may form 
mechanosensitive non-selective cation channels [40,43,44], which could be parts or subunits of 
SACs. They are present in T-tubules of cardiomyocytes and their expression is significantly 
increased in dilated mdx heart [27,45]. TRPC1 is targeted to T-tubules by caveolin-3, a 
scaffolding protein of caveolae, and both proteins are linked to Src-kinase. Caveolin-3 and Src-
kinase are also upregulated in mdx heart and Ca2+ influx through TRPC1 is significantly 
increased when Src is activated by reactive oxygen species (ROS, see cross-talk chapter 
below) [39]. Moreover, overexpression of caveolin-3 in cardiac and skeletal muscle tissue 
causes defects similar to DMD [46,47]. Taken together the evidence above suggests that the 
Caveolin-3-TRPC1-Src complex is likely to be part of a stretch activated Ca2+ (and Na+) influx 
pathway in dystrophy. Skeletal muscle from transgenic mice overexpressing TRPC3 channels 
exhibit increased Ca2+ influx via SOCE and the mice themselves develop severe muscle 
disease reminiscent of DMD. To the contrary, crossing delta-sarcoglycan deletion mice (Scgd-/-), 
another mouse model of muscular dystrophy, with transgenic mice that overexpress a dominant 
negative mutant of TRPC6 attenuates muscular dystrophy [48]. It is possible that 
overexpression of non-conducting mutants of TRPC6 impede the activity of heterotetrameric 
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endogenous TRP complexes, antagonizes SOCE and partially rescues dystrophy. Similarly, 
overexpressing a dominant negative mutant of TRPV2 or ablation of TRPC1 protected 
dystrophic skeletal muscle fibers from the damage caused by eccentric contractions [40,49].  
 
5.1.3. Na+ influx and NCX 
A secondary Ca2+ influx pathway, the Na+-Ca2+ exchanger which in cardiac muscle has a large 
transport capacity, was also held responsible for enhanced Ca2+ influx in mdx cardiomyocytes. It 
contributes to Ca2+ entry in exchange for Na+ that had previously entered via primary stress-
induced pathways (microruptures and SACs) [11] or via voltage-dependent Na+ channels, which 
appear to be stretch sensitive, but down regulated and redistributed in mdx cardiomyocytes 
[50,51]. 
 
Overall, stretch-induced Ca2+ influx through several transmembrane pathways are undoubtedly 
elevated in dystrophic cardiomyocytes. Exact mechanisms underlying upregulation of these 
pathways remain elusive. Oxidative stress may be partly responsible, because it can cause lipid 
peroxidation of sarcolemmal membrane and increased occurrence of microruptures [37]. 
Moreover, oxidation of disulfide bonds near the pore of TRP channels is thought to increase 
Ca2+ influx through some of these channels [52]. The magnitude of the total Ca2+ influx appears 
to be relatively small and not sufficient to entirely explain the excessive intracellular Ca2+ 
responses to mechanical stress observed even early during the development of the disease 
[10,11,28,30]. It has also been reported that at different stages of dystrophic cardiomyopathy 
the cellular phenotype displays hypersensitive EC-coupling [31], increased Ca2+ leak from the 
sarcoplasmic reticulum (SR) and reduced SR Ca2+ load [53,54]. All together, these features 
reflect significant changes in intracellular Ca2+ homeostasis and point to abnormally sensitive 
Ca2+-induced Ca2+ release (CICR) from the SR via RyR channels. 
 
5.2. Cellular Ca2+ signal amplification mechanisms 
Changes in intracellular Ca2+ cycling that are either causal or adaptive were observed in diverse 
models of cardiac disease, including several forms of heart failure [55] . Frequently, Ca2+ 
signaling proteins showed altered levels of expression, most notably the SR Ca2+ ATPase 
(a.k.a. SERCA pump), which commonly has a low abundance in diseased cardiac muscle. 
Moreover,  functional changes in Ca2+ handling were often linked to posttranslational 
modifications of Ca2+ signaling proteins. An important example are the RyRs, which can 
undergo various modifications, such as oxidation, S-nitrosation (sometimes referred to as S-
nitrosylation) and S-glutathionylation, PKA- or CaMKII-dependent phosphorylation [56-58] 
(shown on Diagram 2). The contribution of these posttranslational RyR modifications, their 
functional consequences and disease causing potential are still controversial and need to be 
clarified for each particular disorder. Since all of the modifications mentioned above are likely to 
increase the open probability of RyRs, the sensitized CICR mechanisms observed in mdx 
cardiomyocytes could be the consequence of any (or a combination of several) of those 
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modifications. Similar changes in RyR sensitivity to cytosolic Ca2+ may also be the result of 
increased intracellular or SR luminal Ca2+ levels. Of note, isolated RyR hypersensitivity can lead 
to enhanced diastolic SR Ca2+ leak, which may in turn result in a reduced SR Ca2+ content. This 
reciprocal relationship between RyR sensitivity and SR luminal Ca2+ leads, within limits, to an 
autoregulatory and stabilizing CICR behavior [59]. However, in the case of dystrophic 
cardiomyopathy, this feature may be overridden by the slightly elevated sarcolemmal Ca2+ leak 
into the cell (see above). 
 
5.2.1. Intracellular and SR luminal Ca2+ concentration 
Despite the small but permanent Ca2+ leak into the cardiomyocytes, significant elevations in 
[Ca2+]cyto were detected only in cells isolated from older mdx mice already showing some cardiac 
symptoms on the organ level [27]. Similarly, a significant decrease in SR luminal [Ca2+] was also 
only observed after the onset of cardiac manifestations and at final stages of the disease. In 
contrast, the stress induced augmented Ca2+ signaling and hypersensitive EC-coupling were 
already present in myocytes isolated from mdx pups [60]. Moreover, hearts of 2 months old mdx 
mice are already abnormally vulnerable to mechanical stress and workload-induced damage 
[17]. Based on this sequence of events, it is unlikely that changes in [Ca2+]cyto or SR Ca2+ load, 
which manifest only later in the onset of the dystrophic cardiomyopathy, are driving the early 
cellular abnormalities in mdx mice. Rather they are part of a slowly developing cellular adaptive 
response, which only later becomes maladaptive. 
 
5.2.2. RyR oxidation 
A multitude of cardiac diseases is accompanied by oxidative stress, and the RyRs are known to 
be favored targets for thiol oxidation [61]. It is already well established that oxidative stress 
contributes to skeletal muscle damage in DMD [62,63]. Emerging evidence suggests that this 
may as well be the case for cardiac muscle tissue. Moreover, oxidative stress may serve as a 
pathomechanism that is at least as important for dystrophic cardiomyopathy as the damage 
caused by the abnormalities of Ca2+ signaling, particularly at early stages of the disease [60]. It 
appears   that   the   “mechano-Ca2+ hypothesis”   of   cardiac   dystrophy   should   be   significantly  
modified as previously proposed for skeletal muscle with the introduction   of   a   “two-hit 
hypothesis   of   dystrophy”   [64].   In   cardiomyocytes   isolated   from  mdx animals, ROS production 
was noted to be abnormally high and ROS scavengers could prevent most of the acute Ca2+ 
signaling alterations, suggesting an important role of oxidative stress [28,30,60]. Moreover, in-
vivo treatment of mdx mice with the antioxidant N-acetylcysteine (NAC) reduced ROS levels, 
normalized intracellular Ca2+ homeostasis, improved myofilament function and reduced cardiac 
inflammation and fibrosis [32]. Similar to skeletal muscle, the major source of ROS in dystrophic 
cardiac tissue seems to be NAD(P)H oxidase (NOX), especially during acute mechanical stress 
and at the early stages of the disease (see Diagram 1). Expression levels of several subunits of 
the membrane-bound NOX2 isoform are elevated in dystrophic heart and the activity of the 
enzyme is increased. Consistent with the high expression levels, the ROS production in cardiac 
homogenate was reduced by the NOX inhibitor DPI, but not by oxypurinol or rotenone (inhibitors 
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of ROS production by xanthine oxidase and mitochondria, respectively) [32]. At the single cell 
level, the acute increase in ROS production prompted by mechanical stretch was abolished by 
NOX blockers, either apocynin, DPI or the specific peptide gp91ds that prevents the assembly 
of NOX2 subunits [28,30]. In addition, a stretch-induced increase in ROS generation was 
completely abolished in NOX2-/- mice. The augmented intracellular Ca2+ responses to 
mechanical challenge and hypersensitivity of EC-coupling were normalized by both, ROS 
scavengers and NOX blockers [28,30,31] suggesting that oxidation of RyRs is one of the early 
posttranslational modifications in dystrophy. There are several tentative mechanisms possibly 
underlying enhanced NOX activity in dystrophy. NOX could be activated via phosphorylation by 
Ca2+ sensitive PKC [65-67]. PKC could also be turned on via Angiotensin II receptor signaling, 
which seems to be activated by stretch, even in the absence of an agonist [68]. A direct 
activation of NOX by mechanical stretch exerted by the intracellular tubulin network has also 
been proposed [30]. While the disease progresses further, it is likely that additional ROS 
sources, such as mitochondria, will also contribute to the oxidative stress. Elevated intracellular 
Ca2+ levels could lead to mitochondrial Ca2+ overload, increased ROS leak to the cytosol and 
finally to mitochondrial dysfunction [28]. It should be mentioned again that oxidative stress also 
intensifies plasmalemmal Ca2+ influx (e.g. via membrane lipid peroxidation and activation of TRP 
channels, [39,62]). In addition, it reduces contractility via direct effect on contractile proteins 
[62], both factors contributing to deterioration in dystrophy.  
 
5.2.3. RyR nitrosation 
Relocalization of neuronal nitric oxide synthase (nNOS, NOS1), which is a member of the 
dystrophin associated protein complex, from the plasmalemma to the cytosol along with the 
dysregulation of the NO signaling pathway was also held accountable for the development of 
skeletal muscle pathology in DMD [64]. In addition, it has been reported that hyper-S-nitrosation 
of skeletal muscle RyR1 may be due to an increased activity of inducible NO synthase (iNOS, 
NOS2). Subsequent depletion of the stabilizing protein calstabin-1 from the RyR1 complex 
result in leaky Ca2+ release channels and intracellular Ca2+ overload [69]. A similar sequence of 
events has also been suggested to play an important role in the dystrophic heart [53]. RyRs in 
hearts of mdx mice 35 days and older were found to be hyper-S-nitrosated and calstabin-2 was 
depleted from the RyR complex. This could  be reversed by treatment of mdx mice with the RyR 
channel  stabilizer  “rycal”  S107  or  NAC.  The  latter  also  indicated  that  S-nitrosative modification 
of cysteines on the RyRs may occur via conversion of NO to peroxynitrite after a chemical 
reaction with superoxide anion. In contrast to skeletal muscle where the RyR nitrosation in 
dystrophy closely follows the muscle inflammation and up-regulation of iNOS, the cellular 
pathway leading to hyper-S-nitrosation of RyRs in cardiac dystrophy are yet to be elucidated. 
This scenario may be quite complex as the levels of SR bound NOS1 and caveolae-associated 
endothelial NOS (eNOS, NOS3) are reduced in hearts of dystrophic mice and dogs [19,70] 
while the levels of inflammatory-induced NOS2 are increased only in adult (180 days old) mdx 
mice [53]. It is conceivable that oxidative stress and extensive ROS production by NOX are 
driving forces for RyR S-nitrosation via overproduction of peroxynitrite, at least in early stages of 
the cardiomyopathy. The action of NO within heart cells goes far beyond its involvement in 
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protein S-nitrosation, as it also serves as an important signaling molecule. In particular, NO 
activates guanylyl cyclase to produce cGMP, a second messenger with multiple targets in heart, 
including protein kinase G and proteins directly involved in intracellular Ca2+ homeostasis [71]. 
Reduced NOS activity in dystrophy may therefore down regulate cGMP-signaling pathways. 
Consistent with this possibility, dystrophic mdx mice with overexpression of constitutively active 
guanylyl cyclase were found to have improved cellular integrity, myocardial contractility and 
energy metabolism [72]. Moreover, treatment of young (6-week-old) mdx mice with the 
phosphodiesterase 5 inhibitor sildenafil, which slows down cGMP breakdown, had a similar 
beneficial effect on cardiac function [72]. These in-vivo studies support the notion that 
alterations in NO signaling are key contributors to cardiac dystrophy, although the cellular 
pathways still need to be clarified.  
 
5.2.4. Phosphorylation 
The RyR tetramer forms a large macromolecular complex associated, among others, with 
protein kinases (PKA and CaMKII) and phosphatases (1 and 2A). Some of these enzymes are 
tethered to and therefore held near the RyRs by anchoring proteins. Research on a potential 
role of the RyRs in various cardiac diseases has burgeoned within the last decade, partly driven 
by the discovery of RyR mutations [73] and post-translational modifications. Using mainly 
biochemical and molecular biology approaches, serine 2808 and 2830 on the RyR have been 
identified as possible phosphorylation sites for protein kinase A (PKA), and serine 2814 for 
CaMKII (for reviews see [56-58]). Numerous studies have suggested functional consequences 
of these phosphorylation sites on the RyRs, from the molecular to the cellular level, but also in 
various in-vivo models of cardiac diseases. Changes of RyR phosphorylation status were as 
well being considered as a factor possibly aggravating dystrophic cardiomyopathy. However, an 
initial study found no significant changes in phosphorylation of RyR on Ser-2808 [53] in mdx 
mice up to 6 months of age. In contrast, follow up studies revealed a significant increase in RyR 
phosphorylation by PKA but only in senescent 15 months old animals. At the same time, no 
changes in PKA dependent phosphorylation of phospholamban, a regulatory protein of the SR 
Ca2+ ATPase, could be detected. This suggests a local modification of the RyR phosphorylation 
by more active PKA (or less active phosphatase) tethered to the RyR macromolecular complex 
[74]. Moreover, cross-breeding of mdx mice with RyR2-S2808A mice, in which the PKA 
phosphorylation site S2808 on RyR2 is ablated by alanine substitution, significantly improved 
cardiac performance and rescued function, even in younger animals [74]. At the cellular level,  
SR Ca2+ leak was lowered, and ISO-induced SR Ca2+ release events (e.g. Ca2+ waves) after 
rapid pacing were eliminated in myocytes from 3-4 month old mdx-S2808A mice. Sarcolemmal 
integrity was also improved probably as a result of ameliorated intracellular Ca2+ signaling [14]. 
There are also some reports of CaMKII involvement in the cardiac pathology of dystrophy. This 
would be expected to play a role, since the CaMKII is known to be activated independently of 
Ca2+ by ROS [75]. A preliminary report indicates that cross-breeding of mdx mice with RyR2-
S2814A mice, in which the CaMKII phosphorylation site is ablated, prevents spontaneous SR 
Ca2+ release and sustained ventricular tachycardia following burst pacing [76]. Recent work on 
CaMKII suggests that this enzyme plays a pivotal role in the development of cardiac dystrophy. 
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The presence of the oxidized (i.e. activated [75]) form of CaMKII and phosphorylation of RyR on 
Ser-2814 (but not on Ser-2808) were significantly increased in cardiac tissue isolated from mdx 
pups [60]. Moreover, the augmented intracellular Ca2+ responses to mechanical stress and 
hypersensitivity of EC-coupling were normalized by various CaMKII (but not PKA and NOS) 
inhibitors [60]. Taken together, these results reveal a successive time-dependent evolution of 
the prominent disease pathomechanisms in dystrophic hearts. The in-vivo crossbreeding 
studies confirm that RyR modifications by CaMKII and PKA phosphorylation are driving the 
development of the disease. 
 
Overall, there is increasing evidence indicating a pivotal role of oxidative stress in the 
development and progression of cardiac dystrophy (see Diagram 2). It seems that NOX derived 
ROS signaling has a significant downstream impact on Ca2+ signaling proteins including RyRs. 
RyR oxidation is followed by phosphorylation, first by CaMKII and later by PKA. Nitrosation 
synergistically contributes to abnormal cellular Ca2+ signals and to the degradation of 
cardiomyocyte function. At the terminal stages of cardiac dystrophy RyR hypersensitivity 
together with the sarcolemmal Ca2+ influx results in a serious increase in SR Ca2+ leak 
accompanied by cytosolic and mitochondrial Ca2+ overload [27,28,60]. It seems that the latter 
may be an important turning point which initiates necrotic and apoptotic processes culminating 
in the loss of functional myocytes, development of cardiac fibrosis and reduction in cardiac 
contractility [16]. In parallel, the elevated and unbalanced SR Ca2+ leak leads to a depletion of 
SR Ca2+ content, which will in turn lower Ca2+ transients, thus contributing to diminished force 
production by the surviving cardiomyocytes. In combination with the fibrosis, this could 
eventually impair cardiac contractility further, leading to cardiac failure. 
 
6. Summary 
There are several main conclusions which can be drawn from the studies reviewed above. It is 
becoming more and more clear that several pathomechanisms are involved in the cellular 
damage initiated by the lack of dystrophin, in both skeletal and cardiac muscle. During the slow 
progression of the cardiomyopathy, the activation of these damaging cellular pathways is 
orchestrated in an ever changing pattern and severity. This may arise from progressively 
accumulating mechanical damage to the cells, but also from initially adaptive and later 
maladaptive remodeling of the cardiac muscle cells. Crosstalk between several of the known 
pathomechanisms and Ca2+ signaling pathways may be instrumental for the time-dependent 
evolution of the disease phenotype. If a similar scenario leads to dystrophic cardiomyopathy in 
human patients, this complexity might have repercussions for the development of novel 
therapeutic approaches. At present, there are several preclinical and clinical trials ongoing (e.g. 
treatment   with   antioxidants,   PDE   inhibitors,   ACE   and   Ang   II   receptor   inhibitors,   β-blockers, 
membrane sealants, mitochondrial stabilizers). Each trial is targeting a specific  mechanism 
thought to be of key importance for muscular dystrophy. However, it might be more prudent to 
apply combinational therapies targeting multiple cellular pathologies simultaneously, and to 
adapt the treatment regime to the time-dependent prevalence of each of the pathways. For the 
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development of such multi-pronged treatment plans a more detailed understanding of the basic 
pathomechanisms will be decisive. 
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Figure legends 
 
Diagram 1: Damage and cell death pathways in Dystrophy. The abnormally high activity of 
several signaling pathways, such as ROS/RNS, hyperphosphorylation and Ca2+ signals, triggers 
mitochondrial damage pathways which ultimately may culminate in apoptotic or necrotic cell 
death.  
 
Diagram 2: Signaling pathways involved in Dystrophy. The diagram shows the main 
building blocks of cardiac Ca2+ signaling and EC-coupling. This is combined with the sources, 
pathways and targets of the pathomechanisms relevant for alterations of Ca2+ signaling in 
dystrophic cardiomyopathy. 
Green lines: pathways of oxidative and nitrosative signals (ROS/RNS). Red lines: pathways of 
protein phosphorylation signals. Solid lines depict pivotal and dashed lines depict secondary 
pathways. Dotted lines indicate additional targets of phosphorylation. Abbreviations not 
explained in the review: Cav3: caveolin-3; NaC: voltage-dependent Na+ channel. LTCC: L-type 
Ca2+ channel. AC: adenylate cyclase; MR: membrane ruptures; HNX: mitochondrial proton-
sodium exchanger; MCU: mitochondrial Ca2+ uniporter; ANT: mitochondrial translocase. 
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